{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:48:17Z","timestamp":1790952497883,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.euf.2018.05.004","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T23:30:45Z","timestamp":1527291045000},"page":"760-767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?"],"prefix":"10.1016","volume":"4","author":[{"given":"Tom","family":"Marcelissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Antunes-Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Geavlete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas Barry","family":"Delongchamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1953-7441","authenticated-orcid":false,"given":"Mohammad Sajjad","family":"Rahnama\u2019i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.05.004_bib0005","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.juro.2010.10.048","article-title":"The association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health survey","volume":"185","author":"Link","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0010","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.05.004_bib0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","article-title":"Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature","volume":"65","author":"Sexton","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2018.05.004_bib0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrurol.2013.143","article-title":"Neuromodulation for overactive bladder","volume":"10","author":"Bartley","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0025","article-title":"Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults","volume":"2","author":"Herbison","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euf.2018.05.004_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/nau.20345","article-title":"Sacral nerve stimulation for voiding dysfunction: one institution\u2019s 11-year experience","volume":"26","author":"Sutherland","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.05.004_bib0035","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.juro.2007.07.032","article-title":"Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study","volume":"178","author":"van Kerrebroeck","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0040","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0022-5347(05)67558-1","article-title":"Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety","volume":"163","author":"Hassouna","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0045","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(05)67728-2","article-title":"Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study","volume":"163","author":"Bosch","year":"2000","journal-title":"J Urol"},{"issue":"6 Suppl 1","key":"10.1016\/j.euf.2018.05.004_bib0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0090-4295(00)00597-5","article-title":"Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention","volume":"56","author":"Siegel","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.euf.2018.05.004_bib0055","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.juro.2010.06.142","article-title":"Long-term results of sacral neuromodulation with the tined lead procedure","volume":"184","author":"Marcelissen","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/nau.22544","article-title":"Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder","volume":"34","author":"Siegel","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.05.004_bib0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.mou.0000232047.87803.1e","article-title":"Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction","volume":"16","author":"Pal","year":"2006","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0070","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.juro.2009.12.036","article-title":"Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial","volume":"183","author":"Peters","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0075","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.juro.2009.05.045","article-title":"Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial","volume":"182","author":"Peters","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1525-1403.2012.00504.x","article-title":"Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review","volume":"16","author":"Biemans","year":"2013","journal-title":"Neuromodulation"},{"key":"10.1016\/j.euf.2018.05.004_bib0085","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.juro.2012.11.175","article-title":"Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study","volume":"189","author":"Peters","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000351037","article-title":"Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis","volume":"91","author":"Cui","year":"2013","journal-title":"Urol Int"},{"issue":"2S","key":"10.1016\/j.euf.2018.05.004_bib0095","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.juro.2016.10.109","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"197","author":"Nitti","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.05.004_bib0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/iju.12205","article-title":"Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity","volume":"21","author":"Veeratterapillay","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0110","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/nau.21150","article-title":"Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability","volume":"30","author":"Makovey","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.05.004_bib0115","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","article-title":"Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence","volume":"367","author":"Visco","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2018.05.004_bib0120","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/nau.23170","article-title":"Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)","volume":"36","author":"Apostolidis","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.05.004_bib0125","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-5347(05)64571-5","article-title":"Long-term results of Ingelman-Sundberg denervation procedure for urge incontinence refractory to medical therapy","volume":"168","author":"Westney","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0130","first-page":"126","article-title":"Surgical procedures for the treatment of urge incontinence","volume":"7","author":"Westney","year":"2001","journal-title":"Tech Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0135","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0022-5347(01)61761-0","article-title":"Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation","volume":"161","author":"Leng","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0140","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0145","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jama.2016.14617","article-title":"OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial","volume":"316","author":"Amundsen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2018.05.004_bib0150","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bju.13945","article-title":"Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis","volume":"120","author":"Drake","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.05.004_bib0155","first-page":"8838","article-title":"Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation","volume":"24","author":"Sherif","year":"2017","journal-title":"Can J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0160","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.juro.2013.07.017","article-title":"Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy","volume":"190","author":"Smits","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/nau.22268","article-title":"Does patient age impact outcomes of neuromodulation?","volume":"32","author":"Peters","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.05.004_bib0170","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/bjs.9226","article-title":"Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence","volume":"100","author":"Thin","year":"2013","journal-title":"Br J Surg"},{"key":"10.1016\/j.euf.2018.05.004_bib0175","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.juro.2011.02.2694","article-title":"Sacral neuromodulation as a treatment for chronic pelvic pain","volume":"186","author":"Marcelissen","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0180","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1463-1318.2010.02447.x","article-title":"Sacral neuromodulation: long-term outcome and quality of life in patients with faecal incontinence","volume":"13","author":"Uludag","year":"2011","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.euf.2018.05.004_bib0185","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00384-009-0745-8","article-title":"Sacral neuromodulation for the treatment of fecal incontinence and urinary incontinence in female patients: long-term follow-up","volume":"24","author":"El-Gazzaz","year":"2009","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.euf.2018.05.004_bib0190","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.urology.2011.06.013","article-title":"Can sacral neuromodulation improve minor incontinence symptoms in doubly incontinent patients successfully treated for major incontinence symptoms?","volume":"79","author":"Caremel","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.euf.2018.05.004_bib0195","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/S0140-6736(15)60314-2","article-title":"Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial","volume":"386","author":"Knowles","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2018.05.004_bib0200","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.juro.2010.09.090","article-title":"Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey","volume":"185","author":"Leong","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1472-6963-7-161","article-title":"Patients\u2019 satisfaction and opinions of their experiences during admission in a tertiary care hospital in Pakistan\u2014a cross sectional study","volume":"7","author":"Imam","year":"2007","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.euf.2018.05.004_bib0210","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s11255-015-1100-3","article-title":"Patient preferences for treating refractory overactive bladder in the UK","volume":"47","author":"Hashim","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euf.2018.05.004_bib0215","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00192-014-2360-7","article-title":"Women\u2019s perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment","volume":"25","author":"Balchandra","year":"2014","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2018.05.004_bib0220","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jval.2010.08.006","article-title":"Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder","volume":"14","author":"Arlandis","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.euf.2018.05.004_bib0225","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1464-410X.2010.09905.x","article-title":"Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder","volume":"108","author":"Leong","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.05.004_bib0230","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5489\/cuaj.2711","article-title":"Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective","volume":"9","author":"Hassouna","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euf.2018.05.004_bib0235","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.juro.2009.08.031","article-title":"Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence","volume":"182","author":"Siddiqui","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0240","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00345-014-1401-7","article-title":"Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian healthcare system","volume":"33","author":"Bertapelle","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2018.05.004_bib0245","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/bju.12972","article-title":"The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK","volume":"116","author":"Autiero","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.05.004_bib0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/SPV.0b013e31820e5cf3","article-title":"Use of combined anticholinergic medication and sacral neuromodulation in the treatment of refractory overactive bladder","volume":"17","author":"George","year":"2011","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.euf.2018.05.004_bib0255","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12894-015-0048-z","article-title":"Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex","volume":"15","author":"Su","year":"2015","journal-title":"BMC Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918301214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918301214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:47:41Z","timestamp":1762498061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456918301214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S2405456918301214"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.05.004","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}